ctDNA Breakthroughs in Mesothelioma Care

diagnostic, immunotherapy, imaging

Exploring immunotherapy and ctDNA innovation in mesothelioma, where molecular monitoring may redefine early cancer detection and treatment.

Nov 3^rd • 15 mins listen

ctDNA in DLBCL: A Blueprint for Better Clinical Trials?

Current clinical characteristics and demographics are not sufficient to capture aggressive disease in clinical trials of newly diagnosed DLBCL. Novel tools, such as measurement of tumor burden via ctDNA, are needed. By : Dr. Matthew Maurer.

Apr 10^th • 7 mins listen

Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing

Quest, Diagnostics, MRD, minimal residual testing, precision, biomarker

Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions.

Jul 7^th • 19 mins listen

Rethinking How We Track and Treat Cancer

diagnostic, genomics, breast cancer, antibody drug conjugate, ADC, breast cancer, lung cancer, biomarker

HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.

Jul 13^th • 19 mins listen